Thursday, Dec 15, 1983

Genentech and Major European Pharmaceutical Firm Announce Commercialization Agreement on T-PA

South San Francisco, Calif. -- December 15, 1983 --

Genentech, Inc. announced today that it has concluded an agreement with Boehringer Ingelheim International GmbH regarding the commercialization of human tissue-type plasminogen activator (t-PA) in Europe and certain other markets.

T-PA is a potent and highly specific blood-clot dissolving agent normally found in the body. Through the use of recombinant DNA technology, it can now be manufactured in quantity and evaluated for possible medical applications. Cardiovascular and cerebrovascular diseases are, in combination, one of the world's leading causes of death.

Laboratory and animal studies indicate that t-PA may have significant potential for dissolving life-threatening blood clots in the heart, lungs, legs and arms. The product appears to activate the body's clot-dissolving system to break down a clot and restore blood flow. Human evaluations are expected to begin in the coming months.

Genentech will manufacture and market t-PA under its own label in North America. Boehringer Ingelheim has exclusive rights of commercialization in Europe, the Middle East, Africa, South America and parts of Australasia. As announced previously, rights to market Genentech manufactured t-PA in Japan will be shared by two companies, Mitsubishi Chemical Industries, Ltd. and Kyowa Hakko Kogyo Co., Ltd.

Genentech, Inc. is a leader in the development, manufacture and marketing of recombinant DNA products for pharmaceutical, agricultural and industrial chemical markets.

# # #